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Abstract
The 5 year survival for patients with malignant intracranial non-germinoma germ cell tumors (NGGCT)
which include endodermal sinus tumors, embryonal carcinomas, choriocarcinomas and immature teratomas
is less than 25% following a small resection and radiotherapy. In an effort to improve the survival of these
patients, an approach using an attempt at radical resection where feasible, followed by multi-modality ‘sand-
wich’ therapy (chemotherapy-radiation-chemotherapy) was used to treat 18 newly diagnosed patients be-
tween 1986 and 1994 in a multi-institution study. Fourteen patients had histologically proven NGGCT and four
were presumed NGGCT because of markedly elevated concentrations of serum and/or CSF alpha fetopro-
tein (AFP) and/or beta human chorionic gonadatrophin (b-HCG). The primary tumor was confined to the
pineal region in 12 patients, the suprasellar region in five, and a cerebral hemisphere in one. None of the
patients had central nervous system metastases at diagnosis by MRI imaging of the spine and CSF cytology.
Radical surgical resection was performed initially in 11patients (gross total – 6, subtotal – 5); four had a biopsy
and three had no surgery. All patients then received 3 or 4 cycles of neoadjuvant chemotherapy with cisplatin
(100 mg/m2/cycle) and VP-16 (500 mg/m2/cycle). Of the 12 patients with evaluable disease there were 9 re-
sponses to the neoadjuvant chemotherapy (5 CR, 4 PR); 2 patients had stable disease and 1 progressed during
chemotherapy. Six patients with no evaluable disease after a gross total resection had a continuous complete
response. Seventeen patients received radiation therapy (involved field – 11, involved field + craniospinal – 4,
involved field + whole brain – 2). Twelve patients received 4 cycles post-radiation chemotherapy with vinblas-
tine (6.5 mg/m2/cycle), bleomycin (15 U/m2/cycle), VP-16 (300 mg/m2/cycle, carboplatin (450 mg/m2/cycle). A
total of four patients have died (3 – progressive/recurrent disease, 1 – metabolic). Four year actuarial event-
free and total survival rates are 67% and 74%. This multi-modality adjuvant therapy approach appears to
dramatically improve the outcome of malignant intracranial NGGCT.
Introduction
Primary germ cell tumors are uncommon malignan-
cies in the central nervous system, making up less
than 5% of the histopathological diagnosis of brain
tumors in North American series [1, 2]. They have a
peak incidence in the second and third decade, and
usually arise in midline locations, predominantly in
the pineal or suprasellar regions of the brain [3].
Like their gonadal counterparts, they are histolog-
ically diverse, constituted by several, mostly malig-
nant variants. The germinoma is the most common
of these and although the least differentiated, is the
most readily cured by radiotherapy, with 5 year dis-
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ease-free survival rates approaching 90% in mod-
ern series [4–6].
In contrast, the intracranial malignant non-ger-
minoma germ cell tumors (NGGCT) are distin-
guished as a separate entity because of their rela-
tively poor response to radiotherapy [7]. These tu-
mors include immature teratomas (IT), embryonal
carcinomas (EC), endodermal sinus or yolk sac tu-
mors (EST), choriocarcinomas (CC), and mixed tu-
mors that have various combinations of these his-
tologies. As more radical resections of these tumors
have been attempted recently, with larger speci-
mens available for analysis, the mixed type is being
reported as the most common histological diagnosis
[3]. NGGCT make up approximately 40% of the in-
tracranial germ cell tumors [7].
Children and young adults with these NGGCT
have a much poorer prognosis than do those with
germinomas. With conventional therapy which has
usually been a biopsy or small resection followed by
radiotherapy, long-term disease free survival rates
are less than 25%, with virtually no chance of sur-
vival with some of the histological subtypes [7].
More effective therapy is clearly needed for these
tumors. Anecdotal cases and small series of recur-
rent and newly diagnosed intracranial NGGCT
have shown responses to chemotherapeutic agents
that have been effective in the treatment of system-
ic germ cell tumors [8–12]. This suggests that a re-
gimen using some of these agents could play an im-
portant role in a therapy approach aimed at improv-
ing the long term survival of patients with newly di-
agnosed intracranial NGGCT.
Although intracranial NGGCT are relatively in-
sensitive to radiotherapy compared to germinomas,
some do respond [4]. Moreover, anecdotal reports
of successful treatment of intracranial NGGCT
with chemotherapy also employed radiation [12].
Thus, in an attempt to improve survival of these
patients, we conducted a study in which 18 patients
with newly diagnosed NGGCT were treated with a
multi-modality approach that employed radical
surgical resection where feasible followed by radio-
therapy ‘sandwiched’ between courses of two dif-
ferent chemotherapy regimens.
Clinical materials and methods
Patient population
Eighteen patients with primary intracranial
NGGCT participated in this multi-institution study
between 1986 and 1994. The institutions included:
NYU Medical Center, New York, NY; Children’s
Hospital of Philadelphia, Philadelphia, PA; Univer-
sity of Michigan, Ann Arbor, MI; St. Joseph Hospi-
tal/Marshfield Clinic, Marshfield, Wisconsin, Chil-
dren’s Hospital and Medical Center, Seattle, WA;
Indiana University, Indianapolis, IN; Hackensack
Medical Center, Hackensack, NJ; University of
California Medical Center, Irvine, CA; Cooper
Hospital/University Medical Center, Camden, NJ.
Fourteen of the tumors were histologically-proven
NGGCT (1 IT, 1 CC, 12 mixed) and four were pre-
sumed NGGCT because of elevated (> 50 IU/ml)
levels of serum or CSF tumor markers, alpha feto-
protein (AFP) and/or the beta subunit of human
chorionic gonadatrophin (b-HCG). No tissue was
obtained in three of the latter and one had a biopsy
diagnosed as a germinoma. The histopathological
diagnosis of record was that of the referring institu-
tion. The median age was 12 years (range, 6–24
years). Twelve patients were male and six were fe-
male. The site of origin of the tumor was the pineal
region in 12, the suprasellar region in five, and a ce-
rebral hemisphere in one.
Ten of the 12 patients with pineal tumors present-
ed with a Parinaud’s syndrome and eleven patients
with signs of increased intracranial pressure (head-
ache, lethargy, nausea and vomiting). All five pa-
tients with suprasellar tumors presented with dia-
betes insipidus, three with decreased vision, and
one with precocious puberty. Two of the patients
with suprasellar tumors had signs of increased in-
tracranial pressure at diagnosis. The child with the
cerebral hemisphere tumor presented with a hemi-
paresis.
Eleven of the 18 patients underwent initial rad-
ical surgical resections of their tumors (Table 1).
These were gross total resections (GTR) confirmed
by imaging in six (5 pineal, 1 suprasellar) and sub-
total (> 50%) resections (STR) in five (3 pineal, 1
suprasellar, 1 hemispheric). Four patients under-
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went biopsies and three underwent no surgery. One
of the patients who was initially only biopsied even-
tually underwent a gross total resection after ne-
oadjuvant chemotherapy.
All patients were studied with brain CT scans
with contrast or MRI scans with gadolinium, metri-
zimide myelograms or spine MRI, cytological ex-
amination of cerebrospinal fluid (CSF) and mea-
surement of serum and/or CSF tumor markers,
AFP and b-HCG. None of the 18 patients had evi-
dence of central nervous system dissemination on
brain or spine imaging or on CSF cytological exam-
ination at diagnosis.
Tumor markers, AFP and b-HCG, were mea-
sured prior to therapy in serum and/or cerebrospi-
nal fluid in 14/18 patients (serum only – 5; CSF only –
2; both serum and CSF – 7). Markers were elevated
in 12 of the 14 patients (Table 1). Beta-HCG alone
was elevated in 3 (1 mixed, 1 CC, 1 no biopsy); AFP
was elevated alone in 4 (2 mixed, 1 EST, 1 IT); both
AFP and b-HCG were elevated in 5 patients (3
mixed, 1 presumed mixed with histology of germi-
noma, 1 no biopsy). In all 12 the concentration of at
least one of the markers in serum and/or CSF was
> 50 mIU/ml. In the 6 patients with elevated marker
(s) in whom both CSF and serum marker concentra-
tions were measured, they were > 50 mIU/ml in
both serum and CSF in three, > 50 mIU/ml only in
CSF in two, > 50 mIU/ml only in serum in one. Nei-
ther b-HCG nor AFP were elevated in 2/14 patients
(both mixed). B-HCG and AFP were elevated in
CSF in another 3/18 patients but the exact concen-
trations are unknown (2 mixed, 1 presumed mixed).
Marker concentrations were not measured prior to
a subtotal resection in one patient, but the serum
b-HCG was still > 50 mIU/ml after surgery.
Post-surgery treatment plan
The study protocol (see Treatment schema) pre-
scribed that after any surgery, patients with
NGGCT would receive 4 cycles of neoadjuvant che-
motherapy administered as follows: cisplatin,
20 mg/m2/day and etoposide, 100 mg/m2/day, on 5
consecutive days at the beginning of each cycle. Cy-
cles would be repeated every 4 weeks. A response
determination using the imaging modality that orig-
inally identified the tumor would be made after 2
and 4 cycles. If residual disease remained after 4 cy-
cles, a second resection was recommended regard-
less of tumor marker status.
Patients then would receive radiation therapy.
Radiotherapy at a dosage of 5500 cGy would be giv-
en to the involved field. Craniospinal therapy
would be given to patients with disseminated dis-
ease at diagnosis, with focal boosts given to areas of
measurable metastases. There was considerable
controversy about the need for craniospinal irradia-
tion in patients with non-disseminated disease, and
this decision was ultimately left to the treating in-
stitution. Response determination by brain imaging
would be made 4 weeks after radiotherapy if eva-
luable disease existed prior to radiotherapy.
After completion of radiotherapy, patients would
receive four 6 weeks cycles of further adjuvant che-
motherapy as follows: Day 1: vinblastine, 4 mg/m2;
Days 1 and 2: bleomycin, 15 U/m2 given as a contin-
uous infusion over the 2 days; Days 3, 4, and 5: car-
boplatin, 100 mg/m2/day and etoposide, 150 mg/m2/
day. Response determination would again be per-
formed after 4 cycles.
After completion of therapy, patients would be
followed at intervals with neurological examin-
ations, imaging studies, CSF cytologic examination
and measurement of tumor markers. No further
therapy would be given to patients who remained in
continuous remission.
Results
Response to pre-radiation chemotherapy
Eighteen patients received either three or four cy-
cles of pre-radiation chemotherapy. There were
nine objective responses among the 12 patients with
evaluable disease (Table 1). Five patients had a
complete response (CR) after 4 cycles and four had
a partial response (PR) (Figure 1). Two patients
with evaluable disease had stable residual disease
(SD) after 4 cycles of chemotherapy and one had
progressive disease during chemotherapy. The re-
maining six patients without evaluable disease had
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Figure 1. T1-weighted coronal gadolinium-enhanced MRI of a suprasellar NGGCT at diagnosis (a), and showing a complete response
after 4 cycles of neoadjuvant chemotherapy (b).
continued complete responses (cCR) to pre-radi-
ation chemotherapy, after gross total resections.
One of these developed increased enhancement
near the original tumor bed after two cycles of che-
motherapy but had no residual tumor at second-
look surgery, and the area of enhancement had di-
minished after the 4th cycle of chemotherapy. One
patient with a cCR died of complications of dia-
betes insipidus after 3 cycles of chemotherapy.
Tumor markers correlated with response to che-
motherapy. There were seven patients with evalua-
ble disease in whom marker(s) were initially elevat-
ed and again measured after 4 cycles of neoadjuvant
chemotherapy. Tumor markers became negative in
six patients who had an objective response (4 CR
and 2 PR), and decreased but were still elevated
above normal in one patient with stable disease.
Response to radiotherapy
Seventeen patients received radiotherapy after the
neoadjuvant chemotherapy. This consisted of in-
volved field radiation as prescribed by the protocol,
in 11 patients. Four patients also received craniospi-
nal therapy and two received whole brain radiation
because of institutional preference, although none
had disseminated disease. Of the 8/17 patients with
radiographically evaluable disease before starting
radiotherapy, one had a CR (after a PR to chemo-
therapy), 6 had stable disease, and one continued to
progress and died before completion of radiother-
apy. Of the 9/17 without evaluable disease, all had
cCRs after radiotherapy.
Response to post-radiation chemotherapy
Twelve patients completed post-radiation chemo-
therapy; of the 4/12 with evaluable disease, one had
a CR (after a PR to neoadjuvant chemotherapy and
SD after radiotherapy), and three had SD; the 8/12
with no evaluable disease had cCRs after post-radi-
ation chemotherapy. Seven of the 19 patients did
not complete post-radiation chemotherapy. Two
died before receiving it, three refused further treat-
ment after radiation, one continues to receive ther-
apy, and one had discontinuation of therapy be-
cause of exacerbation of a pre-existing muscle dis-
ease.
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Figure 2. Outcome of NGGCT – Five year actuarial event-free
and total survival.
Status at completion of all therapy
Thus, by the time all therapy was terminated, the
disease status of the 16 survivors was as follows: 13/
16 had no evidence of disease (NED) as a result of a
CR at some time during the chemotherapy or radi-
ation (7) or a cCR after a gross total resection (6);
3/16 had measurable radiographic evidence of sta-
ble residual disease of which the maximum dia-
meters on MRI were 2 cm, 2.5 cm and 3 cm.
Outcome
The median length of follow-up of these patients
was 4.1 years. Fourteen of the 18 patients initially
treated are alive; eleven are in continuous remis-
sion, 10 with no evidence of disease (NED) and one
with residual stable disease (SD); three survivors
developed progressive or recurrent disease 2, 2 2/3,
and 7 years from diagnosis. Four patients have died,
three of progressive or recurrent disease and one of
metabolic complications of diabetes insipidus. Five
year actuarial event-free and total survival rates are
67 ± 9% and 74 ± 10% (SE) (Figure 2).
Ten of the 14 survivors had evaluable disease
when they received the neoadjuvant chemotherapy,
to which nine had an objective response (5 CR, 4
PR). Six of the nine responders remain in contin-
uous remission and three have progressed or re-
curred at 2 years, 2 2/3 years, and 7 years after hav-
ing had PRs to initial chemotherapy; one of these
progressed only at the primary site and two re-
curred in brain outside the radiation field without
local recurrence. The single survivor with evaluable
disease and no objective response to pre-radiation
chemotherapy initially had recurrent disease after a
gross total resection before receiving the neoadju-
vant chemotherapy. This patient had stable disease
(residual pineal mass measuring 3 cm in maximal
diameter on MRI) after neoadjuvant chemother-
apy, which has remained unchanged after radio-
therapy, post-radiation chemotherapy and for 5
years since diagnosis. The four survivors without
evaluable disease before pre-radiation chemother-
apy have had continuous complete remissions
(cCR) with no evidence of disease throughout and
since completion of all prescribed therapy.
Of the three patients who died of progressive or
recurrent disease, two had evaluable disease prior
to chemotherapy. One of these had progressive dis-
ease during pre-radiation chemotherapy and died
of continued progressive disease during an attempt
to deliver radiotherapy, 4 months after diagnosis.
The other had no response after 3 cycles of chemo-
therapy (SD) and then underwent a gross total sur-
gical resection of viable pineal region mixed
NGGCT. This patient had continued remission
through the completion of involved-field radiother-
apy and post-radiation chemotherapy, but devel-
oped metastatic disease in the spine without local
recurrence and died 16 months following diagnosis.
The third patient who eventually died of disease
had a GTR and a cCR throughout all prescribed
therapy but developed diffuse leptomeningeal me-
tastases in the spine and brain without local recur-
rence and died 13 months after diagnosis.
Tumor markers were measured in three of the pa-
tients at the time of progression or recurrence, and
all were again elevated after they had previously be-
come normal in response to therapy.
No treatment-related mortality occurred during
this study. Two patients developed venous throm-
botic disease during pre-radiation chemotherapy.
One had severe systemic veno-occlusive disease
treated with anticoagulation and a Greenfield vena
caval filter, which resolved within several weeks.
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The other had sagittal sinus and one lateral sinus
thrombosis associated with headaches. The symp-
toms promptly resolved with heparinization and
the patient remained on coumadin throughout the
neoadjuvant chemotherapy and radiotherapy with-
out further problems. One patient developed grade
2 pulmonary toxicity from bleomycin and did not
receive the 4th cycle of post-radiation chemother-
apy. No grade 3 or 4 otological toxicity was reported
in any of the patients. One patient who appeared to
have a pre-existing metabolic myopathic disease
with low grade elevations of CPK and muscle
cramping prior to diagnosis of this tumor, devel-
oped acute rhabdomyolysis and myoglobinuria
during the first cycle of post-radiation chemother-
apy.
Discussion
Patients with primary malignant intracranial
NGGCT historically have had a much poorer prog-
nosis for long term survival than those with germi-
nomas. Patients with these tumors have a very low
likelihood of being cured with conventional ther-
apy, which in most cases has been a biopsy or small
resection and high dose/high volume radiotherapy.
In a meta-analysis of previously published cases,
virtually no long term survivors at five years were
reported with several types of NGGCT (CC, EC,
EST) treated with radiotherapy alone, with an over-
all survival rate of less than 25% [7]. The multi-
modality approach of our study was initiated in 1986
in an effort to improve on the poor outcome of pa-
tients with these tumors.
Radical surgical resection was encouraged on
this protocol for several reasons. Sampling error
from a small piece of tissue may lead to the misdiag-
nosis of a NGGCT as a germinoma, as was demon-
strated in patient # 4 in this series. The determina-
tion of the concentrations of the serum and CSF tu-
mor markers, AFP and b-HCG, may compensate
for this and it appears that when tumor makers are
elevated above 50–100 IU/ml, regardless of histo-
pathology, the tumors behave like NGGCTs and
should be treated as such [13, 14]. There was correla-
tion between the degree of marker elevation and
NGGCT histopathology among our patients. In all
with histologically proven NGGCT and marker ele-
vation in serum and/or CSF, the concentration of at
least one marker was greater than 50 mIU/ml. It
should be noted that where both CSF and serum
concentrations were measured, the elevated con-
centration was sometimes seen only one or the
other, pointing to the importance of measurement
from both sources for diagnosis of these tumors.
Moreover, markers are not always elevated with
NGGCT [15] as was also illustrated in patients # 2
and # 18. Thus, a larger tissue specimen makes the
diagnosis more secure.
It was less certain whether therapeutic benefit
would be derived from a more aggressive surgical
resection. The prevailing wisdom in oncology is that
decreasing tumor burden by surgical means in-
creases the curative potential of subsequent radio-
therapy and chemotherapy, and gives the best
chance for these treatments to be effective [16]. Al-
though surgery on brain tumors can rarely be as
radical as that for systemic tumors, technological
advances in surgery and perioperative care have
greatly improved the safety of a surgical approach
to pineal or suprasellar tumors, and has made a
more radical resection feasible in many cases [4, 16].
Whether radical surgical resection of these tu-
mors contributed to good outcome in this study
could not be determined given the relatively small
number of patients and use of multi-modality ther-
apy. Although 3 of the 7 patients who underwent a
gross total resection eventually developed further
disease, only one had local progression while 2/3 re-
curred outside the primary site. Likewise, 3 of the 4
patients who had subtotal resections developed fur-
ther disease but only one had progressive disease
locally while two recurred only outside the primary
site. This data still leaves open the possibility that
radical surgery could benefit local disease control.
Recently reported abstracted data from an interna-
tional study suggested improved early survival with
radical surgery [4], although the combined data re-
ported from several other European studies of 50
NGGCT showed no positive correlation between
the extent of surgery and outcome [14].
Several sources of data support the addition of
chemotherapy to a multi-modality therapy regimen
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aimed at improving outcome with NGGCT. High
risk systemic germ cell tumors with non-germinoma
histological features have been cured with regimens
that included various multi-agent platinum-based
regimens [10, 11, 17–23]. Anecdotal reports and
small studies suggest that recurrent and newly diag-
nosed NGGCT of the brain respond to similar plati-
num-based regimens [8, 9, 12, 24, 25]. The neoad-
juvant strategy of the initial chemotherapy has sev-
eral potential advantages. In patients with evalua-
ble disease it permits determination of the efficacy
of specific agents. Response of evaluable disease to
chemotherapy may help to stratify patients with re-
gard to risk and possible need for more intensive
additional therapy. Neoadjuvant therapy could also
have synergistic interaction with subsequent radi-
ation and offers potential control of occult metasta-
ses when involved-field radiation is used.
The response of the tumors to this neoadjuvant
pre-radiation chemotherapy was excellent, with
nine of the twelve patients with evaluable disease
showing objective responses. An objective re-
sponse to the neoadjuvant therapy was predictive
of outcome. All nine patients with an objective re-
sponse are alive at the time of follow-up; six are
event-free and 3 have progressed or recurred.
There were two objective responses to therapy giv-
en after the initial chemotherapy (one CR to radi-
ation after a PR to chemotherapy, and one CR to
post-radiation chemotherapy after a PR to initial
chemotherapy and SD after radiation). No conclu-
sions about these later responses can be made both
because of the very small numbers and the difficulty
in interpreting responses to sequential therapy. The
platinum dose of the neoadjuvant therapy may be
critical to the response rate and ultimate outcome.
Recently reported combined data from several Eu-
ropean studies showed a four-year survival rate of
86%, comparable to that of our study, in patients
who also received 400 mg/m2 cumulative cisplatin
dose before radiotherapy, compared to only 56% in
a 200 mg/m2 cumulative cisplatin group [14]. The
degree of response to the neoadjuvant chemother-
apy may also be significant to outcome. All three
patients with an objective response to the initial
chemotherapy but subsequent progression, had
only PRs and not CRs to the therapy.
Conversely the lack of an objective response to
the platinum-based neoadjuvant therapy in our
study correlated with a poorer outcome. Two of
three patients without a response were among the
three patients who eventually died of their disease.
Whether the post-radiation chemotherapy regimen
used in this protocol was essential to the overall
good outcome is difficult to determine from such a
single arm multi-modality study. The combined da-
ta from the European studies with survival rates
comparable to ours do not answer this question
either, because they employed slightly different
multi-agent platinum-based regimens given in vari-
ous orders, each to a relatively small number of pa-
tients [14]. However, the lack of an objective re-
sponse or of a complete response in particular
cases, to the neoadjuvant chemotherapy given here
supports the need for different additional therapy
in this subgroup. The optimal combination and in-
tensity of chemotherapy agents and radiotherapy
remains to be determined. The addition of an alky-
lating agent such as cyclophosphamide, to which
some intracranial and other germ cell tumors have
also shown responsiveness, is a logical direction [8].
The chemotherapy in this regimen was well toler-
ated. There were no deaths thought to be related to
toxicity from chemotherapy. The development of
venous thrombosis in 2 patients during neoadjuvant
chemotherapy is of interest. Both of these had re-
markably high elevations of the tumor marker b-
HCG (36,000 and 19,000 mIU/ml). Whether this
complication could be the result of some interac-
tion between the markers and the specific chemo-
therapy agents is unknown. Another patient who
received cisplatin chemotherapy for an intracranial
NGGCT has been reported with venous thrombot-
ic complications as well [12].
Although the relative radio-resistance of
NGGCT justified using a more aggressive treat-
ment approach for these tumors, there seemed still
to be merit to including radiotherapy in a multi-
modality regimen in this very high risk group of pa-
tients. Some NGGCT’s do respond to radiotherapy,
and five year survival in two smaller series using ra-
diation alone was recently reported at 33–45% [4,
6]. Radiation therapy may potentially be synergistic
with chemotherapy, as well.
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Because patients with objective responses to ne-
oadjuvant chemotherapy had good outcomes treat-
ed on this protocol, the question of whether the ra-
diation is crucial to the improved prognosis in this
subgroup, might be raised. In data from combined
European intracranial NGGCT series, nine of ten
patients treated with platinum-based chemother-
apy, alone, died of their disease, while the 27 pa-
tients treated with platinum regimens plus radio-
therapy had much better outcomes. In this group, 4
year event-free survivals were 56% and 86% with
low dose and high dose platinum plus radiotherapy,
comparable to that of our study [14]. Although this
data was not specifically analyzed with respect to
chemotherapy response, taken together with our
data, it supports the conclusion that combination
chemotherapy based on high dose platinum plus ra-
diation therapy is the most effective treatment to
date. Unless different adjuvant chemotherapy is
shown to independently contribute to improved
outcome for NGGCT, radiation probably should
not be eliminated from this therapy regimen. The
tumor progression seen in three of our patients
more than two years from diagnosis also demon-
strates that long-term follow-up is crucial to assess-
ing the efficacy of any treatment regimen for this
type of tumor.
The pattern of recurrence in our patients was
noteworthy with regard to optimal radiotherapy
volume. Two of the three patients who died of their
disease had spinal metastases with no recurrence at
the primary site. Neither had received spinal irradi-
ation. Moreover, two of three survivors with pro-
gressive disease progressed intracranially outside
the radiation field without local recurrence (one su-
prasellar, one temporal lobe). This raises consider-
ation of a role for craniospinal radiation in the treat-
ment of these tumors, at least for patients without a
complete response to initial chemotherapy who
may be at higher risk for neuroaxis spread. Other
reports of isolated neuroaxis failures with intracra-
nial NGGCT afer chemotherapy support this idea,
as well [26, 27].
On the basis of our experience with NGGCT, we
conclude that this combined multi-modality re-
gimen of neoadjuvant cisplatin/etoposide chemo-
therapy, radiation and further adjuvant chemother-
apy is effective treatment for these tumors. Al-
though the number of patients treated on this re-
gimen was not large, their median follow-up is long
and they have had a better outcome than patients
historically treated with radiotherapy alone. The
response rate to the neoadjuvant chemotherapy
was high and predictive of long-term survival in
these patients. Radical surgical resection may con-
tribute to disease control, and obtaining a generous
tissue sample for accurate histopathological diag-
nosis is important in most cases.
Since all patients received at least local radiation,
this study can not absolutely establish the necessity
of radiotherapy for the improved outcome. How-
ever, based on our data taken together with the ex-
perience of others where patients treated with high
dose platinum regimens but without radiotherapy
had a much worse prognosis, we believe that in-
volved-field radiation, at least, should continue to
be included in this successful regimen [14]. We also
conclude that patients who do not respond and per-
haps those who do not have a complete response to
the neoadjuvant chemotherapy of this regimen are
at significantly higher risk for progression and
death from their tumors. Different chemotherapy
agents and possibly craniospinal radiation, need to
be considered for the treatment regimens of such
patients.
Acknowledgements
The authors wish to acknowledge J. Russel Geyer,
M.D., Roger C. Packer, M.D., Arther J. Provisor,
M.D., Eric D. Kramer, M.D., Violet Shen, M.D., H.
James Nickerson, M.D., Beverly Rossi Ryan, M.D.
and their institutions, who treated patients on this
protocol.
References
1. Bloom HJ: Primary intracranial germ cell tumors. Clin On-
col 2: 233–257, 1983
2. Jellinger K: Primary intracranial germ cell tumors. Acta
Neuropathol 25(4): 291–306, 1973
3. Sano K, Matsutani M, Seto T: So-called intracranial germ
Please indicate author’s corrections in blue, setting errors in red
110512 NEON ART.NO 679-95 (505) ORD.NO 234505
80
cell tumors: Personal experiences and a theory of their path-
ogenesis. Neurol Res 11(2): 118–126, 1989
4. Hoffman HJ, Otsubo H, Hendrick EB, Humphreys RP,
Drake JM, Becker LE, Greenberg M, Jenkin D: Intracranial
germ-cell tumors in children. J Neurosurg 74(4): 545–551,
1991
5. Lindstadt D, Wara WM, Edwards MS, Hudgins RJ, Sheline
GE: Radiotherapy of primary intracranial germinomas: The
case against routine craniospinal irradiation. Int J Radiat
Oncol Biol Phys 15(2): 291–297, 1988
6. Matsutani M, Takakura K, Sano K: Primary intracranial
germ cell tumors: Pathology and treatment. Prog Exp Tu-
mor Res 30: 307–312, 1987
7. Jennings MT, Gelman R, Hochberg F: Intracranial germ-
cell tumors: Natural history and pathogenesis. J Neurosurg
63(2): 155–167, 1985
8. Allen JC, Kim JH, Packer RJ: Neoadjuvant chemotherapy
for newly diagnosed germ-cell tumors of the central nervous
system. J Neurosurg 67(1): 65–70, 1987
9. Allen JC, Bosl G, Walker R: Chemotherapy trials in recur-
rent primary intracranial germ cell tumors. J Neurooncol
3(2): 147–152, 1985
10. DeLeo MJ, Greco FA, Hainsworth JD, Johnson DH: Late
recurrences of long-term survivors of germ cell neoplasms.
Cancer 62(5): 985–988, 1988
11. Borge N, Fossa SD, Ous S, Stenwig AE, Lien HH: Late re-
currence of testicular cancer. J Clin Oncol 6: 1248–1253, 1988
12. Kida Y, Kobayashi T, Yoshida J, Kato K, Kageyama N: Che-
motherapy with cisplatin for AFP-secreting germ-cell tu-
mors of the central nervous system. J Neurosurg 65(4): 470–
475, 1986
13. Balmaceda C, Finlay J, Heller G, Vliamis V, Maher P, Ro-
senblum M: Prognostic factors at diagnosis in patients with
primary CNS germ cell tumors (CNS GCT): A report of an
international collaborative trial of chemotherapy (meeting
abstract). Proc Ann Meeting Am Soc Clin Oncol 13: A494,
1994
14. Calaminus G, Bamberg M, Baranzelli MC, Benoit Y, di
Montezemolo LC, Fossati-Bellani F, Jurgens H, Kuhl HJ,
Lenard HG, Curto ML et al.: Intracranial germ cell tumors:
A comprehensive update of the European data. Neurope-
diatrics 25(1): 26–31, 1994
15. Packer RJ, Sutton LN, Rosenstock JG, Rorke LB, Bilaniuk
LT, Zimmerman RA, Littman PA, Bruce DA, Schut L: Pine-
al region tumors of childhood. Pediatrics 74(1): 97–102, 1984
16. Allen JC: Controversies in the management of intracranial
germ cell tumors. Neurol Clin 9(2): 441–452, 1991
17. Kobayashi T, Yoshida J, Ishiyama J, Noda S, Kito A, Kida Y:
Combination chemotherapy with cisplatin and etoposide
for malignant intracranial germ-cell tumors. An experimen-
tal and clinical study. J Neurosurg 70: 676–681, 1989
18. Barlow JJ, Lele SB: Etoposide (VP-16) plus cisplatin
(DDP): A new active chemotherapeutic combination in pa-
tients with stage III–IV ovarian adenocarcinoma. J Surg On-
col 32(1): 43–45, 1986
19. Bosl GJ, Yagoda A, Whitmore WF Jr, Sogani P, Herr H, Vu-
grin D, Dukeman M, Golbey R: VP-16 213 and cisplatin in
the treatment of patients with refractory germ cell tumors.
Am J Clin Oncol 7(4): 327–330, 1984
20. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y,
Young RC: A randomized trial of standard chemotherapy V.
A high-dose chemotherapy regimen in the treatment of
poor prognosis nonseminomatous germ-cell tumors. J Clin
Oncol 6(6): 1031–1040, 1988
21. Ozols RF, Deisseroth AB, Javadpour N, Barlock A, Mess-
erschmidt GL, Young RC: Treatment of poor prognosis
nonseminomatous testicular cancer with a ‘high dose’ plati-
num combination chemotherapy regimen. Cancer 51(10):
1803–1807, 1983
22. Vugrin D, Herr HW, Whitmore WF Jr, Sogani PC, Golbey
RB: VAB-6 combination chemotherapy in disseminated
cancer of the testis. Ann Int Med 95(1): 59–61, 1981
23. Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH:
Cisplatin-based combination chemotherapy for disseminat-
ed germ cell tumors: Long-term follow-up. J Clin Oncol
6(8): 1239–1247, 1988
24. Graziano SL, Paolozzi FP, Rudolph AR, Stewart WA, Elba-
dawi A, Comis RL: Mixed germ-cell tumor of the pineal re-
gion. Case report. J Neurosurg 66(2): 300–304, 1987
25. Watterson J, Priest JR: Control of extraneural metastasis of
a primary intracranial nongerminomatous germ-cell tumor.
Case report. J Neurosurg 71: 601–604, 1989
26. Senan S, Rampling R, Kaye SB: Malignant pineal terato-
mas: A report on three patients and the case for craniospinal
irradiation following chemotherapy. Radiotherapy Oncol
22(3): 209–212, 1991
27. Wilson ER, Takei Y, Bikoff WT, O’Brein MS, Tindall GT,
Boehm WM: Abdominal metastases of primary intracranial
yolk sac tumors through ventriculoperitoneal shunts: Re-
port of three cases. Neurosurgery 5(3): 356–364, 1979
Address for offprints: P.L. Robertson, L3208 Women’s Hospital,
University of Michigan Medical Center, Ann Arbor, MI 48109-
0302, USA
